|
|||||
|
|
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia |
|
| Authors: | Kiran Naqvi MD Elias Jabbour MD Jeffrey Skinner BS MHA Kristin Anderson BS Sara Dellasala BS Musa Yilmaz MD Alessandra Ferrajoli MD Prithviraj Bose MD Philip Thompson MBBS Yesid Alvarado MD Nitin Jain MBBS Koichi Takahashi MD Jan Burger MD Zeev Estrov MD Gautam Borthakur MBBS Naveen Pemmaraju MD Shilpa Paul Pharm D Jorge Cortes MD Hagop M. Kantarjian MD |
| Affiliation: | The University of Texas MD Anderson Cancer Center, Houston, Texas |
| Abstract: | |
| Keywords: | chronic myeloid leukemia complete cytogenetic response dasatinib major molecular response |